# Cefdinir-Induced Liver Injury: A Case Report

**Authors:** Muhammad Areeb Ashfaq, Hajira Z Malik, Leena Patel, Cesar Moreno

PMC · DOI: 10.7759/cureus.81523 · 2025-03-31

## TL;DR

A woman developed liver injury after taking cefdinir, a type of antibiotic, highlighting the rare but possible side effect of this medication.

## Contribution

This case report adds to the limited literature on cefdinir-induced liver injury and emphasizes the importance of medication history in diagnosing liver issues.

## Key findings

- A 40-year-old woman developed drug-induced liver injury after taking cefdinir for a urinary tract infection.
- Liver enzymes were significantly elevated, and liver biopsy showed hepatocellular changes consistent with DILI.
- No other underlying liver disease was found, supporting the diagnosis of cefdinir-induced injury.

## Abstract

Cephalosporins are very rarely known to cause drug-induced liver injury (DILI). We present the case of a healthy 40-year-old female who developed DILI after completing a course of cefdinir, a third-generation cephalosporin, to treat a urinary tract infection. A 40-year-old female with no past medical history presented to the emergency department with a chief complaint of epigastric pain and jaundice for the last four days. A workup at an urgent care revealed hyperbilirubinemia and elevated liver enzymes, prompting this visit. She had completed a five-day course of cefdinir for a urinary tract infection three weeks prior to her visit. Physical examination revealed a vitally stable patient with scleral icterus and no other positive findings. Laboratory workup was significant for total bilirubin 4.3 mg/dL, direct bilirubin 0.7 mg/dL, ALP 130 unit/L, ALT 546 unit/L, and AST 213 unit/L. Serum hepatitis panel, ferritin, ceruloplasmin, alpha-1 antitrypsin, and autoimmune workup were within normal limits. Ultrasound and CT of the abdomen and magnetic resonance cholangiopancreatography did not reveal any pathology. Liver biopsy demonstrated hepatocellular adaptive changes and mild bile duct epithelial damage, suggestive of DILI. This case highlights the importance of obtaining a thorough medical history, including recent medication use, drug dose, and time of symptom onset, for a patient presenting with elevated liver enzymes. This case also emphasizes keeping a broad list of differential diagnoses when managing patients with elevated liver enzymes.

## Linked entities

- **Chemicals:** cefdinir (PubChem CID 6915944)
- **Diseases:** drug-induced liver injury (MONDO:0005359), urinary tract infection (MONDO:0005247)

## Full-text entities

- **Genes:** CP (ceruloplasmin) [NCBI Gene 1356] {aka AB073614, CP-2}, SERPINA1 (serpin family A member 1) [NCBI Gene 5265] {aka A1A, A1AT, AAT, PI, PI1, PRO2275}, ATHS (atherosclerosis susceptibility (lipoprotein associated)) [NCBI Gene 470] {aka ALP}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}
- **Diseases:** hyperbilirubinemia (MESH:D006932), DILI (MESH:D056486), icterus (MESH:D007565), Liver Injury (MESH:D017093), urinary tract infection (MESH:D014552), autoimmune (MESH:D001327), epigastric pain (MESH:D010146)
- **Chemicals:** Cefdinir (MESH:D000077525), bilirubin (MESH:D001663), Cephalosporins (MESH:D002511)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12043275